Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer
- 1 June 2016
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 141 (3) , 405-409
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Ovarian Cancer, Version 2.2013Journal of the National Comprehensive Cancer Network, 2013
- Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendationsAmerican Journal of Obstetrics and Gynecology, 2011
- Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trialThe Lancet, 2010
- Clinical Utility of Positron Emission Tomography/Computed Tomography in the Evaluation of Suspected Recurrent Ovarian Cancer in the Setting of Normal CA-125 LevelsInternational Journal of Gynecological Cancer, 2010
- Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?European Journal of Nuclear Medicine and Molecular Imaging, 2010
- Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation☆Gynecologic Oncology, 2003
- Use of CA-125 to Define Progression of Ovarian Cancer in Patients With Persistently Elevated LevelsJournal of Clinical Oncology, 2001
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of Clinical Oncology, 1991
- Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecologic Oncology, 1990
- Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trialsBritish Journal of Cancer, 1989